Pilot Trial to Determine the Feasibility of a One Step Sentinel Lymph Node Biopsy Procedure Using Radiolabeled Methylene Blue (IND 70,627)
This study proposes the use of a newly developed experimental radioactive dye (radiolabeled
methylene blue). On the day of surgery, the patient receives a single injection of the
experimental radioactive dye after anesthesia. The injection will be in the location around
the breast tumor. The surgeon makes a small cut in the armpit on the side of the cancer and
is able to locate the lymh nodes that collect drainage from the cancerous area by detecting
lymph nodes with higher radioactivity using a hand-held detector (a Geiger counter-like
device) and/or visually identifying lymph nodes stained blue by the dye. These lymph nodes
are then removed and analyzed by pathologists for the presence of cancer.
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
The Number of Participants That Have Sentinel Nodes Which Are Radioactive or Blue, or Radioactive and Blue or Have Efferent Blue Lymphatics Leading up to the Sentinel Node(s)
intraoperatively; up to 6 hours
Yes
Eugene A Woltering, MD
Principal Investigator
LSU Health Sciences Center - New Orleans LA
United States: Food and Drug Administration
LSU #6169
NCT00784849
November 2004
June 2011
Name | Location |
---|---|
University Medical Center | Lafayette, Louisiana 70506 |
LSU Interim Hospital | New Orleans, Louisiana 70112 |